Idiopathic, Refractory Sweet’s Syndrome Associated with Common Variable Immunodeficiency: a Case Report and Literature Review
Purpose of Review
Sweet’s syndrome (SS) is classically considered a hypersensitivity reaction often associated with autoimmune disorders and malignancy. SS has also been increasingly reported to occur with immunodeficiencies. We present a case of treatment-refractory, systemic SS as the initial manifestation in a young child with common variable immunodeficiency (CVID). We also review current literature about SS and concurrent immunodeficiencies and autoimmunity in CVID patients.
Few case reports exist regarding the co-occurrence of Sweet’s syndrome and primary immunodeficiencies. SS is characterized by a pro-inflammatory state with a neutrophil predominance resulting in a spectrum of clinical manifestations. CVID is a multifactorial antibody deficiency that can be associated with autoimmunity, which some studies have proposed to be secondary to altered CD21 expression. SS occurring in patients with CVID has been infrequently reported, and one case study demonstrated improvement of Sweet’s associated skin lesions with immunoglobulin replacement. In our case, the patient had multi-system SS refractory to multiple immunomodulatory therapies. To our knowledge, this is the first report of the effective and safe use of intravenous tocilizumab and oral lenalidomide to treat SS in a child with CVID. Immunoglobulin replacement reduced the frequency of infections and may have contributed to the opportunity to wean the immunosuppressive therapies for Sweet’s syndrome.
Sweet’s syndrome as an initial manifestation of co-occurring immunodeficiencies is rare, and providers need a high index of suspicion. In addition, treatment of SS associated with an immunodeficiency can be a challenge. Treatment with immunoglobulin replacement reduces the frequency of infections, and in some patients with concurrent SS may improve skin lesions and reduce the need for immunomodulator therapy. Further study is necessary to better understand the pathogenesis of CVID in patients with SS and to identify possible biomarkers that predict who with SS are at risk for developing hypogammaglobulinemia.
KeywordsNeutrophilic dermatoses Sweet’s syndrome Common variable immunodeficiency Primary immunodeficiency Hypogammaglobulinemia
Acute generalized exanthematic pustulosis
B cell activating factor receptor
Common variable immunodeficiency
Chronic granulomatous disease
Granulocyte-colony stimulating factor
Granulomatous lymphocytic interstitial lung disease
Human immunodeficiency virus
Severe combined immunodeficiency
Systemic lupus erythematosus
Transmembrane activator calcium-modulator and cyclophilin ligand interactor
We would like to express our gratitude to Dr. Michael Hershfield, Professor of Medicine and Biochemistry at Duke University for his assistance in evaluating our patient for ADA2 deficiency.
Compliance with Ethical Standards
Conflict of Interest
Drs. Cook, Googe, Wu, Zdanski, and Burkhart declare that they have no conflicts of interest.
Human and Animal Rights
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent was obtained from individual(s) discussed in this case report.
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 25.Kawakami T, Ohashi S, Kawa Y, Takahama H, Ito M, Soma Y, et al. Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active Behcet disease: implication in neutrophil apoptosis dysfunction. Arch Dermatol. 2004;140:570–4.CrossRefGoogle Scholar
- 36.Cunningham RC. The many faces of common variable immunodeficiency. Hematol Am Soc Hematol Educ Program. 2012;2012:301–5.Google Scholar
- 45.Zhang L, Radigan L, Salzer U, Behrens TW, Grimbacher B, Diaz G, et al. Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes. J Allergy Clin Immunol. 2007;120:1178–85.CrossRefGoogle Scholar